Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management

Haematologica

Volumn 99, Issue 11, 2014, Pages 1671-1676

  Rampton, David ^a   Folkersen, Joergen ^b   Fishbane, Steven ^c   Hedenus, Michael ^d   Howaldt, Stefanie ^e   Locatelli, Francesco ^f   Patni, Shalini ^g   Szebeni, Janos ^h   Weiss, Guenter ⁱ  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Medbusiness   (Denmark)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d SUNDSVALL HOSPITAL   (Sweden)

^e Research Institute for IBD HaFCED GmbH and CoKG   (Germany)

^f A MANZONI HOSPITAL   (Italy)

^g BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CORTICOSTEROID; IMMUNOGLOBULIN E; IPRATROPIUM BROMIDE; IRON; IRON DEXTRAN;

ALLERGIC REACTION; ANXIETY; ARTICLE; ATOPY; COMORBIDITY; DISEASE ACTIVITY; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FIRST TRIMESTER PREGNANCY; FLUSHING; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IRON DEFICIENCY ANEMIA; LUPUS ERYTHEMATOSUS; MASTOCYTOSIS; RESUSCITATION; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK MANAGEMENT; WHEEZING; ANEMIA, IRON-DEFICIENCY; COMPLICATION; DISEASE MANAGEMENT; DRUG HYPERSENSITIVITY; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; DISEASE MANAGEMENT; DRUG HYPERSENSITIVITY; HUMANS; INCIDENCE; IRON; RISK FACTORS;

EID: 84908459097     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.111492     Document Type: Article

References (31)

1. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369(9572):1502-4.
2. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010;2010:338-47.
3. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. European Medicines Agency 2013. EMA/579491/2013:1-3. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf
4. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6.
5. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378-82.
6. Critchley J, Dunbar Y. Adverse events associated with intravenous iron infusion (lowmolecular-weight iron dextran and iron sucrose): a systematic review. Transfusion Altern Transfusion Med. 2007;9(1):8-36.
7. Bailie GR, Verhoef JJ. Differences in the reporting rates of serious allergic adverse events from intravenous iron by country and population. Clin Adv Hematol Oncol. 2012;10(2):101-8.
8. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm. 2012;69(4):310-20.
9. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85(9):650-4.
10. Cherlow GM, Winkelmayer WC. Commentary: on the relative safety of intravenous iron formulations. New answers, new questions. Am J Hematol. 2010;85(9): 643-4.
11. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005; 216(2-3):106-21.
12. Novey HS, Pahl M, Haydik I, Vaziri ND. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72(3):224-8.
13. Fleming LW, Stewart WK, Parratt D. Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients. Nephrol Dial Transplant. 1992;7(1):35-9.
14. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur J Nanoparticles. 2012;1(1); 33-53.
15. Szebeni J, Baranyi L, Sávay S, Bodó M, Milosevits J, Alving CR, et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol Heart Circ Physiol. 2006;290(3):H1050-8.
16. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480-91.
17. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13-37.
18. Pavord S, Myers B, Robinson S Allard S, Strong J, Oppenheimer C; British Committee for Standards in Haematology. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156(5):588-600.
19. Reveiz L, Gyte GML, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2011 Oct 5;(10): CD003094.
20. Blake DR, Lunec J, Ahern M, Ring EF, Bradfield J, Gutteridge JM. Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis. 1985;44(3):183-8.
21. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol. 2013;9(4):205-15
22. Runge VM. Safety of magnetic resonance contrast media. Top Magn Reson Imaging. 2001;12(4):309-14.
23. Edwards A, Elwyn, G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002;324(7341):827-30.
24. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466-9.
25. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371-6.
26. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28(4):529-34.
27. Resuscitation Council UK. Emergency treatment of anaphylactic reactions. Guidelines for healthcare providers. Available from: https://www.resus.org.uk/pages/reaction.pdf
28. Ring J, Grosber M, Mohrenschlager M, Brockow K. Anaphylaxis: acute treatment and management. Chem Immunol Allergy. 2010;95:201-10.
29. Vogel WH. Infusion reactions, diagnosis assessment, management. Clin J Oncol Nurs. 2010;14(2):E10-21.
30. Goss JE, Chambers CE, Heupler FA Jr. Systemic anaphylactoid reactions to iodinated contrast media during cardiac catheterization procedures: guidelines for prevention, diagnosis, and treatment. Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn. 1995;34(2):99-104.
31. Gafter-Gvili A, Steensma DP, Auerbach M. Should the ASCO/ASH guidelines for the use of intravenous iron in cancer-and chemotherapy-induced anemia be updated? J Nat Compr Cancer Netwk. 2014; 12(5):657-64.